Fluorine in PDB 8f0p: Structure of VSD4-NAV1.7-Navpas Channel Chimera Bound to the Hybrid Inhibitor Gne-1305

The binding sites of Fluorine atom in the Structure of VSD4-NAV1.7-Navpas Channel Chimera Bound to the Hybrid Inhibitor Gne-1305 (pdb code 8f0p). This binding sites where shown within 5.0 Angstroms radius around Fluorine atom.
In total only one binding site of Fluorine was determined in the Structure of VSD4-NAV1.7-Navpas Channel Chimera Bound to the Hybrid Inhibitor Gne-1305, PDB code: 8f0p:

Fluorine binding site 1 out of 1 in the Structure of VSD4-NAV1.7-Navpas Channel Chimera Bound to the Hybrid Inhibitor Gne-1305


Mono view


Stereo pair view

A full contact list of Fluorine with other atoms in the F binding site number 1 of Structure of VSD4-NAV1.7-Navpas Channel Chimera Bound to the Hybrid Inhibitor Gne-1305 within 5.0Å range: probe atom residue distance (Å) B Occ A:F1610 b:19.9 occ:1.00 F01 A:X7L1610 0.0 19.9 1.0 C13 A:X7L1610 1.3 3.1 1.0 C14 A:X7L1610 2.3 8.6 1.0 C12 A:X7L1610 2.4 0.4 1.0 O01 A:X7L1610 2.5 15.2 1.0 S01 A:X7L1610 3.0 16.2 1.0 CZ A:PHE1264 3.3 6.5 1.0 S02 A:X7L1610 3.4 17.1 1.0 CG A:ARG1268 3.5 2.7 1.0 CD A:ARG1268 3.5 0.0 1.0 C11 A:X7L1610 3.6 3.3 1.0 C09 A:X7L1610 3.6 1.6 1.0 NE A:ARG1268 3.7 2.4 1.0 CE1 A:PHE1264 3.8 4.9 1.0 N03 A:X7L1610 4.0 7.2 1.0 CE1 A:TYR1203 4.1 0.0 1.0 CZ A:TYR1203 4.1 3.0 1.0 C10 A:X7L1610 4.1 6.1 1.0 O02 A:X7L1610 4.1 7.3 1.0 C15 A:X7L1610 4.1 0.0 1.0 CE2 A:PHE1264 4.2 8.9 1.0 CD1 A:TYR1203 4.4 4.0 1.0 CE2 A:TYR1203 4.4 4.2 1.0 OH A:TYR1203 4.4 7.1 1.0 CD2 A:TYR1203 4.7 2.3 1.0 CG A:TYR1203 4.7 1.8 1.0 N02 A:X7L1610 4.7 6.2 1.0 CZ A:ARG1268 4.8 5.3 1.0 CB A:ALA1251 4.8 5.7 1.0 CB A:ARG1268 4.8 0.0 1.0 CD1 A:PHE1264 5.0 6.6 1.0

M.Kschonsak, C.C.Jao, C.P.Arthur, A.L.Rohou, P.Bergeron, D.F.Ortwine, S.J.Mckerrall, D.H.Hackos, L.Deng, J.Chen, T.Li, P.S.Dragovich, M.Volgraf, M.R.Wright, J.Payandeh, C.Ciferri, J.C.Tellis. Cryo-Em Reveals An Unprecedented Binding Site For Na V 1.7 Inhibitors Enabling Rational Design of Potent Hybrid Inhibitors. Elife V. 12 2023.
ISSN: ESSN 2050-084X
PubMed: 36975198
DOI: 10.7554/ELIFE.84151